Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24878758 | 0.84 | KDM4E (0.32) | CYP1A2GAACYP2C19KDM4ETSHR | |
| SCHEMBL17695172 | 0.84 | KDM4E (0.32) | CYP1A2GAACYP2C19KDM4ETSHR | |
| SCHEMBL16006579 | 0.84 | KDM4E (0.32) | CYP1A2GAACYP2C19KDM4ETSHR | |
| SCHEMBL15708301 | 0.75 | TRPM2 (0.37) | CYP1A2GAACYP2C19KDM4EALDH1A1 | |
| SCHEMBL21643202 | 0.75 | MAPK1 (0.35) | GAACYP2C19KDM4EALDH1A1HTT | |
| SCHEMBL16006723 | 0.75 | MAPK1 (0.35) | GAACYP2C19KDM4EALDH1A1HTT | |
| SCHEMBL19875674 | 0.75 | MAPK1 (0.35) | GAACYP2C19KDM4EALDH1A1HTT | |
| SCHEMBL23793623 | 0.75 | MAPK1 (0.35) | GAACYP2C19KDM4EALDH1A1HTT | |
| SCHEMBL21407652 | 0.75 | TRPM2 (0.37) | CYP1A2GAACYP2C19KDM4EALDH1A1 | |
| SCHEMBL19875669 | 0.75 | MAPK1 (0.35) | GAACYP2C19KDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149408-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | POLR2H, POLR2E, EIF2AK2 | CYP1A2 2965/4885GAA 651/4885CYP2C19 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.